All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drbergofficial on TikTok · 43s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drbergofficial's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00What ocempic does to the body is it increases a certain receptor called GLP1, which helps slow down
  2. 0:09digestion, thereby decreasing your appetite, cravings, so you're no longer hungry and you can eat less
  3. 0:17and lose more weight. It even improves the beta cells of the pancreas to help restore insulin levels.
  4. 0:24In fact, it's been known to improve insulin resistance. And anything that improves insulin
  5. 0:29resistance will help you lose weight. It has some interesting effects in the liver too. It actually
  6. 0:34helps a person stop making so much sugar. Okay, that's called gluconeogenesis. And also it helps
  7. 0:40slow the breakdown of sugar in the liver.

Dr. Berg's Ozempic 'natural alternatives' claim fact-checked

Dr. Eric Berg

TikTok creator

470.7K viewsWatch on TikTok

Quick answer

Semaglutide (Ozempic, Wegovy) is an FDA-approved GLP-1 receptor agonist that reduces appetite through central and peripheral mechanisms, slows gastric emptying, suppresses hepatic gluconeogenesis, and stimulates glucose-dependent insulin secretion. The video's mechanism description is broadly accurate but contains pharmacological imprecisions, particularly around GLP-1 receptor activation versus the hormone itself. The caption's claim that unspecified natural alternatives produce the same effects without side effects is not supported by current clinical evidence.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dr. Berg's Ozempic 'natural alternatives' claim fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dr. Berg's Ozempic 'natural alternatives' claim fact-checked" from Dr. Eric Berg. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic, Wegovy) is an FDA-approved GLP-1 receptor agonist that reduces appetite through central and peripheral mechanisms, slows gastric emptying, suppresses hepatic gluconeogenesis, and stimulates glucose-dependent insulin secretion.

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic is a versatile product that can assist in various wa." In this clip, the useful excerpt is: "What ocempic does to the body is it increases a certain receptor called GLP1, which helps slow down digestion, thereby decreasing your appetite, cravings, so you're no longer hungry and you can eat less and lose more weight." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP-1 trial (Wilding et al.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (Ozempic, Wegovy) is an FDA-approved GLP-1 receptor agonist that reduces appetite through central and peripheral mechanisms, slows gastric emptying, suppresses hepatic gluconeogenesis, and stimulates glucose-dependent insulin secretion.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Ozempic, Wegovy) is an FDA-approved GLP-1 receptor agonist that reduces appetite through central and peripheral mechanisms, slows gastric emptying, suppresses hepatic gluconeogenesis, and stimulates glucose-dependent insulin secretion. The video's mechanism description is broadly accurate but contains pharmacological imprecisions, particularly around GLP-1 receptor activation versus the hormone itself. The caption's claim that unspecified natural alternatives produce the same effects without side effects is not supported by current clinical evidence.
  • Semaglutide activates the GLP-1 receptor; it does not increase GLP-1 the hormone. This distinction matters when evaluating whether natural GLP-1 boosters can replicate its effects.
  • The STEP-1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced 14.9% average body weight reduction in non-diabetic adults, a benchmark no supplement has matched in equivalent trials.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide activates the GLP-1 receptor; it does not increase GLP-1 the hormone. This distinction matters when evaluating whether natural GLP-1 boosters can replicate its effects.
  • The STEP-1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced 14.9% average body weight reduction in non-diabetic adults, a benchmark no supplement has matched in equivalent trials.
  • Hepatic gluconeogenesis suppression is a real and clinically meaningful effect of GLP-1 receptor agonists, confirmed in multiple meta-analyses including Zhu et al. (2021, Diabetes Care).
  • Beta cell preservation from semaglutide is supported in animal models and some human data, but describing this as restoring insulin levels overstates current human evidence.
  • The SUSTAIN-6 trial (Marso et al., 2016, NEJM) showed semaglutide reduced major cardiovascular events, an outcome no natural alternative has replicated in a comparable trial.
  • GLP-1 receptor agonists carry a documented side effect profile including nausea, vomiting, and pancreatitis risk. Any claim of equivalent natural alternatives with zero side effects requires clinical trial evidence, not anecdote.
  • Berberine shows modest GLP-1 pathway activity in early studies but has not demonstrated equivalency to semaglutide in any peer-reviewed head-to-head weight loss or glycemic trial as of 2024.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drbergofficial actually say?

Dr. Berg claims that Ozempic works by increasing a receptor called GLP-1, which slows digestion, reduces appetite, and leads to weight loss. He also says it improves beta cells in the pancreas, restores insulin levels, reduces insulin resistance, and has liver effects including reducing gluconeogenesis and slowing sugar breakdown.

The core pitch in the caption is that "natural alternatives" exist that produce the same results without side effects. The short video is essentially a mechanism explainer used as a funnel to his website. That framing matters, because it shapes how loosely he handles the science.

To be fair, the mechanism description he gives is not fabricated. Most of what he says tracks with established pharmacology. But there are some notable imprecisions that matter clinically, and the "no side effects" claim in the caption is flatly unsupported.

Does the science back this up?

Mostly, yes, with important caveats. Semaglutide is a GLP-1 receptor agonist, meaning it binds to and activates GLP-1 receptors rather than simply "increasing" them. That is a meaningful pharmacological distinction. The appetite suppression, gastric emptying delay, and glycemic benefits are well-documented.

The liver effects he describes are real. GLP-1 receptor agonists have been shown to reduce hepatic glucose output, partly through suppression of glucagon and partly through direct hepatic signaling. A 2021 meta-analysis by Zhu et al. in Diabetes Care confirmed reductions in fasting glucose and HbA1c that are consistent with reduced gluconeogenesis. The beta cell claim is also supported: research published by Peyot et al. and others has shown semaglutide has cytoprotective effects on pancreatic beta cells in animal models, though human data on functional beta cell restoration is more limited and ongoing.

Insulin resistance improvement is well-established in the clinical trial record, including the SUSTAIN and STEP trial programs, and is partly a downstream effect of weight loss itself.

What did they get wrong (or right)?

The biggest error is in the mechanism framing. Berg says Ozempic "increases a certain receptor called GLP-1." That is imprecise in a way that misleads viewers. GLP-1 is a hormone, not a receptor. The receptor is the GLP-1 receptor. Ozempic activates it, it does not increase it or the hormone. A small distinction? Not really, because it affects how people understand why natural GLP-1 boosters would or would not work similarly.

He also says it "helps restore insulin levels," which is vague to the point of being misleading. Semaglutide stimulates glucose-dependent insulin secretion. It does not restore baseline insulin production in a clinically durable way independent of continued drug use. The beta cell preservation data in humans is promising but not conclusive enough to call it restoration.

What he gets right: the appetite suppression mechanism, the gastric emptying effect, the gluconeogenesis point, and the insulin resistance connection are all directionally accurate. Credit where it is due.

What is not addressed but should be: the caption's claim of "no side effects" for natural alternatives is unsupported and irresponsible. GLP-1 receptor agonists have a well-documented side effect profile including nausea, vomiting, and pancreatitis risk. Any alternative claiming equivalent benefit with zero side effects needs evidence, not marketing copy.

What should you actually know?

Semaglutide's mechanisms are genuinely multi-pathway. It is not just an appetite suppressant. The hepatic and pancreatic effects are real and are part of why it performs better than older diabetes drugs in cardiovascular outcome trials, including the SUSTAIN-6 trial published in the New England Journal of Medicine (Marso et al., 2016).

The phrase "natural alternatives" does a lot of heavy lifting with very little evidence behind it. Berberine, for example, is frequently cited in this space. It does have some GLP-1 pathway activity in limited studies, but no head-to-head trial shows equivalency to semaglutide for weight loss or glycemic control. Claiming no side effects ignores berberine's own GI side effect profile and drug interaction potential.

If you are considering GLP-1 therapy, the mechanism Dr. Berg describes is real. But the implicit suggestion that you can replicate it with supplements and skip the side effects is not supported by clinical evidence. Talk to a licensed provider who can review your full history before making any changes.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Eric Berg · TikTok creator

470.7K views on this video

Ozempic is a versatile product that can assist in various ways, such as slowing digestion, enhancing GLP-1 receptors, and boosting insulin sensitivity - leading to weight loss. However, there are natu

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide activates the glp-1 receptor; it does not increase glp-1?

Semaglutide activates the GLP-1 receptor; it does not increase GLP-1 the hormone. This distinction matters when evaluating whether natural GLP-1 boosters can replicate its effects.

What does the video say about the step-1 trial (wilding et al., 2021, nejm) showed semaglutide?

The STEP-1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced 14.9% average body weight reduction in non-diabetic adults, a benchmark no supplement has matched in equivalent trials.

What does the video say about hepatic gluconeogenesis suppression?

Hepatic gluconeogenesis suppression is a real and clinically meaningful effect of GLP-1 receptor agonists, confirmed in multiple meta-analyses including Zhu et al. (2021, Diabetes Care).

What does the video say about beta cell preservation from semaglutide?

Beta cell preservation from semaglutide is supported in animal models and some human data, but describing this as restoring insulin levels overstates current human evidence.

What does the video say about the sustain-6 trial (marso et al., 2016, nejm) showed semaglutide?

The SUSTAIN-6 trial (Marso et al., 2016, NEJM) showed semaglutide reduced major cardiovascular events, an outcome no natural alternative has replicated in a comparable trial.

What does the video say about glp-1 receptor agonists carry a documented side effect profile including?

GLP-1 receptor agonists carry a documented side effect profile including nausea, vomiting, and pancreatitis risk. Any claim of equivalent natural alternatives with zero side effects requires clinical trial evidence, not anecdote.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Eric Berg, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.